2 active not recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Social Behavior: new trials by email Literature Review of Social Behavior trials Research Report on Social Behavior
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunological Tolerance in Patients With Mismatched Kidney Transplants Donor CD34+, CD3+. and belumosudil - End Stage Kidney Disease, Immunological Tolerance | Phase 1 | Active not recruiting | University of California, Los Angeles | 16 | 2023-07-07 | 2025-11-26 |
| Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients QEL-001 - Rejection; Transplant, Liver, Liver Failure | Phase 1 / Phase 2 | Active not recruiting | Quell Therapeutics Limited | 33 | 2022-01-21 | 2026-07-02 |
Rejection, Psychology (2) · Kidney Failure, Chronic (1) · Liver Diseases (1) · Liver Failure (1) · Renal Insufficiency, Chronic (1)
Behavior (2) · Chronic Disease (1) · Digestive System Diseases (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Hepatic Insufficiency (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Renal Insufficiency (1) · Urogenital Diseases (1) · Urologic Diseases (1)
CD3 Complex (1) · belumosudil (1)
Quell Therapeutics Limited (1) · University of California, Los Angeles (1)
Belgium (1) · Spain (1) · United Kingdom (1) · United States (1)